Drug-drug interaction study to explore importance of CYP3A4 and OATP1B1 as factors determining pharmacokinetics of atorvastati
- Conditions
- healthy male subjects
- Registration Number
- JPRN-UMIN000002477
- Lead Sponsor
- Clinical trial Center,Kitsato University East Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 8
Not provided
1)Any hypersensitivities to atorvastatin,midazolam,pravastatin, straconazole or rifampicin. 2)hepatic disease requiring treatment. 3)acute narrow-angle glaucoma 4)QT prolongation over 460ms. 5)Use of medicine or health product including Saint John's wort 2 weeks before pre-dose. 6)Intake of fruit food and drink including grapefruit juice, orange juice or apple juice from 7 days before pre-dose. 7)Participation to any other clinical reseach in the past 3 months. 8)Donating over 200 ml of blood in the past 1 month or over 400ml of blood in the past 3 months. 9)Positive tests of serological reaction for syphilis, HIV antigen and antibody, HBs antigen or HCV antibody. 10)Any allergy to drug and food 11)Drug abuse or positive drug screening 12)Any condition that, in the opinion of the investigator, would make the patient unsuitable for the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method